NR 601 Week 5 Quiz: Thyroid Management & Diabetes Care
| 250 Verified Questions | 2026/2027 Edition
NR 601 Week 5 Quiz 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam prep document for NR 601 Week 5 Quiz covers essential topics in thyroid
management and diabetes care. With 250 verified questions and answers, it provides a thorough review
of pathophysiology, pharmacotherapy, and clinical management of thyroid disorders and diabetes
mellitus. Designed for Chamberlain University's advanced practice nursing curriculum, this resource
ensures mastery of key concepts for optimal exam performance.
Key Features:
Thyroid disorders: hypothyroidism, hyperthyroidism, thyroid nodules, and thyroiditis
Diabetes mellitus: type 1, type 2, gestational diabetes, and diabetic ketoacidosis
Pharmacologic management: levothyroxine, methimazole, insulin regimens, and oral hypoglycemics
Monitoring and complications: thyroid function tests, HbA1c, hypoglycemia, and long-term complications
Patient education and lifestyle modifications for thyroid and diabetes care
Evidence-based guidelines from ATA, ADA, and AACE
Updates for 2026:
- Updated to reflect 2026-2027 clinical practice guidelines for thyroid and diabetes management
- Incorporated latest insulin analogs and SGLT2 inhibitor recommendations
- Revised rationales to align with current evidence-based practice
- Added new questions on continuous glucose monitoring and thyroid cancer management
- Enhanced distractor explanations to clarify common misconceptions
Abstract:
This exam preparation document is meticulously curated for NR 601 Week 5 Quiz at Chamberlain University,
focusing on thyroid management and diabetes care. It comprises 250 verified questions and answers that cover the
full spectrum of thyroid disorders, including hypothyroidism, hyperthyroidism, thyroiditis, and thyroid nodules, as
well as diabetes mellitus types 1 and 2, gestational diabetes, and acute complications such as diabetic ketoacidosis.
Each question is accompanied by a detailed rationale that explains the correct answer and analyzes common
distractors, reinforcing critical thinking and clinical reasoning. The content is aligned with the latest guidelines
from the American Thyroid Association (ATA), American Diabetes Association (ADA), and American Association
of Clinical Endocrinologists (AACE). This resource is designed to help advanced practice nursing students achieve
a comprehensive understanding of pathophysiology, pharmacotherapy, monitoring, and patient education essential
for safe and effective clinical practice. By engaging with these questions, students will be well-prepared for the
quiz and future clinical encounters involving thyroid and diabetes management.
Keywords:
NR 601, Thyroid management, Diabetes care, Exam prep, Verified questions, Chamberlain University, Advanced
practice nursing, Endocrinology
Answer Format:
Each question is presented in a multiple-choice format with four options. The correct answer is clearly indicated,
followed by a detailed rationale explaining why it is correct and why the other options are incorrect. Distractor
explanations highlight common errors and misconceptions to enhance learning.
Compliance Checklist:
All questions are verified and aligned with 2026-2027 clinical guidelines
Page 1
, Content covers essential topics for NR 601 Week 5 Quiz
Rationales are evidence-based and referenced to current literature
Distractors are designed to test critical thinking and clinical judgment
Document is formatted for easy navigation and study
Suitable for self-assessment and group review
Content Area Overview:
Content Area Questions Key Topics Weight
Thyroid Disorders 1-100 Hypothyroidism, Hyperthyroidism, 40%
Thyroiditis, Thyroid Nodules, Thyroid
Cancer
Diabetes Mellitus 101-200 Type 1 Diabetes, Type 2 Diabetes, 40%
Gestational Diabetes, Diabetic Ketoacidosis,
Hyperosmolar Hyperglycemic State
Pharmacotherapy & Monitoring 201-230 Levothyroxine, Methimazole, Insulin 12%
Regimens, Oral Hypoglycemics, SGLT2
Inhibitors, GLP-1 Agonists
Patient Education & 231-250 Lifestyle Modifications, Hypoglycemia 8%
Complications Management, Long-term Complications,
Sick Day Rules
Page 2
,Q1. A patient with type 2 diabetes on metformin 1000 mg BID and glipizide 10 mg BID presents with acute
kidney injury (creatinine 3.0 mg/dL, eGFR 22 mL/min/1.73 m²). Which adjustment to the diabetes regimen
is most appropriate?
A. Continue metformin at reduced dose; discontinue glipizide.
B. Discontinue metformin; continue glipizide at same dose.
C. Discontinue both metformin and glipizide; start insulin glargine.
D. Continue both metformin and glipizide; add sitagliptin.
Correct Answer: C. Discontinue both metformin and glipizide; start insulin glargine.
Rationale: Metformin is contraindicated when eGFR <30 mL/min/1.73 m² due to risk of lactic acidosis. Glipizide,
a sulfonylurea, accumulates in renal impairment and can cause prolonged hypoglycemia. Both should be stopped.
Insulin glargine is safe in renal impairment because it does not require renal clearance.
Why Wrong:
A - Metformin is contraindicated at this eGFR; continuing it poses lactic acidosis risk.
B - Glipizide can accumulate and cause severe hypoglycemia in renal impairment.
D - Sitagliptin requires dose adjustment for renal impairment and does not address the need to stop metformin
and glipizide.
Reference: American Diabetes Association. (2023). Standards of Medical Care in Diabetes-2023. Diabetes Care,
46(Suppl 1), S1-S291.
Q2. A patient with type 1 diabetes on multiple daily injections reports nocturnal hypoglycemia (glucose 52
mg/dL at 3 AM) despite reducing bedtime insulin. Continuous glucose monitoring reveals a nadir at 2 AM
followed by hyperglycemia at 7 AM. Which pathophysiologic process best explains this pattern?
A. Somogyi effect
B. Dawn phenomenon
C. Waning insulin effect
D. Rebound hyperglycemia from glucagon excess
Correct Answer: A. Somogyi effect
Rationale: The Somogyi effect involves a rebound hyperglycemia following an episode of hypoglycemia, due to
counterregulatory hormone release (glucagon, epinephrine). The dawn phenomenon is a morning rise without
preceding hypoglycemia. Waning insulin effect would cause gradual hyperglycemia without a nadir.
Why Wrong:
B - Dawn phenomenon is a morning rise without preceding hypoglycemia, not a rebound.
C - Waning insulin effect would cause gradual hyperglycemia, not a nadir at 2 AM.
D - Rebound hyperglycemia from glucagon excess is part of the Somogyi effect, but the question asks for the
overall pattern name.
Reference: Cryer, P. E. (2013). Hypoglycemia in diabetes: Pathophysiology, prevalence, and prevention. American
Diabetes Association.
Page 3
, Q3. A patient with subclinical hypothyroidism (TSH 7.2 mIU/L, free T4 1.0 ng/dL) is being started on
levothyroxine. The patient also takes ferrous sulfate 325 mg daily for iron deficiency anemia. Which
instruction is most critical to ensure proper absorption?
A. Take levothyroxine with food to reduce GI upset.
B. Take levothyroxine and ferrous sulfate together to increase compliance.
C. Take levothyroxine at least 4 hours apart from ferrous sulfate.
D. Increase levothyroxine dose by 25% to compensate for interaction.
Correct Answer: C. Take levothyroxine at least 4 hours apart from ferrous sulfate.
Rationale: Iron supplements bind to levothyroxine in the GI tract, forming an insoluble complex that reduces
absorption. They should be separated by at least 4 hours. Taking with food also impairs absorption. Increasing
dose is not a standard recommendation; separation is preferred.
Why Wrong:
A - Food, especially high-fiber or iron-rich foods, also impairs levothyroxine absorption.
B - Taking together worsens the interaction, reducing bioavailability.
D - Dose adjustment is not recommended; separation is the standard approach.
Reference: Lehne, R. A. (2026). Pharmacology for Nursing Care (12th ed., Ch. 49). Elsevier.
Q4. A patient with Graves' disease is being treated with methimazole. Three weeks into therapy, the patient
develops fever, sore throat, and oral ulcers. Laboratory results show WBC 1,200/µL, absolute neutrophil
count 400/µL. What is the most appropriate immediate action?
A. Continue methimazole and add a broad-spectrum antibiotic.
B. Discontinue methimazole immediately and hospitalize for agranulocytosis management.
C. Switch to propylthiouracil and monitor CBC weekly.
D. Administer granulocyte colony-stimulating factor (G-CSF) and continue methimazole.
Correct Answer: B. Discontinue methimazole immediately and hospitalize for agranulocytosis management.
Rationale: Methimazole can cause agranulocytosis (absolute neutrophil count <500/µL), a life-threatening adverse
effect. The drug must be discontinued immediately. Hospitalization is required for infection management and
possible G-CSF therapy. Switching to propylthiouracil is not safe because of cross-reactivity.
Why Wrong:
A - Continuing methimazole in the setting of agranulocytosis is dangerous; infection management alone is
insufficient.
C - Propylthiouracil has cross-reactivity and can also cause agranulocytosis.
D - G-CSF may be used, but methimazole must be discontinued first.
Reference: Burch, H. B., & Cooper, D. S. (2015). Management of Graves disease: A review. JAMA, 314(23),
2544-2554.
Page 4
| 250 Verified Questions | 2026/2027 Edition
NR 601 Week 5 Quiz 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam prep document for NR 601 Week 5 Quiz covers essential topics in thyroid
management and diabetes care. With 250 verified questions and answers, it provides a thorough review
of pathophysiology, pharmacotherapy, and clinical management of thyroid disorders and diabetes
mellitus. Designed for Chamberlain University's advanced practice nursing curriculum, this resource
ensures mastery of key concepts for optimal exam performance.
Key Features:
Thyroid disorders: hypothyroidism, hyperthyroidism, thyroid nodules, and thyroiditis
Diabetes mellitus: type 1, type 2, gestational diabetes, and diabetic ketoacidosis
Pharmacologic management: levothyroxine, methimazole, insulin regimens, and oral hypoglycemics
Monitoring and complications: thyroid function tests, HbA1c, hypoglycemia, and long-term complications
Patient education and lifestyle modifications for thyroid and diabetes care
Evidence-based guidelines from ATA, ADA, and AACE
Updates for 2026:
- Updated to reflect 2026-2027 clinical practice guidelines for thyroid and diabetes management
- Incorporated latest insulin analogs and SGLT2 inhibitor recommendations
- Revised rationales to align with current evidence-based practice
- Added new questions on continuous glucose monitoring and thyroid cancer management
- Enhanced distractor explanations to clarify common misconceptions
Abstract:
This exam preparation document is meticulously curated for NR 601 Week 5 Quiz at Chamberlain University,
focusing on thyroid management and diabetes care. It comprises 250 verified questions and answers that cover the
full spectrum of thyroid disorders, including hypothyroidism, hyperthyroidism, thyroiditis, and thyroid nodules, as
well as diabetes mellitus types 1 and 2, gestational diabetes, and acute complications such as diabetic ketoacidosis.
Each question is accompanied by a detailed rationale that explains the correct answer and analyzes common
distractors, reinforcing critical thinking and clinical reasoning. The content is aligned with the latest guidelines
from the American Thyroid Association (ATA), American Diabetes Association (ADA), and American Association
of Clinical Endocrinologists (AACE). This resource is designed to help advanced practice nursing students achieve
a comprehensive understanding of pathophysiology, pharmacotherapy, monitoring, and patient education essential
for safe and effective clinical practice. By engaging with these questions, students will be well-prepared for the
quiz and future clinical encounters involving thyroid and diabetes management.
Keywords:
NR 601, Thyroid management, Diabetes care, Exam prep, Verified questions, Chamberlain University, Advanced
practice nursing, Endocrinology
Answer Format:
Each question is presented in a multiple-choice format with four options. The correct answer is clearly indicated,
followed by a detailed rationale explaining why it is correct and why the other options are incorrect. Distractor
explanations highlight common errors and misconceptions to enhance learning.
Compliance Checklist:
All questions are verified and aligned with 2026-2027 clinical guidelines
Page 1
, Content covers essential topics for NR 601 Week 5 Quiz
Rationales are evidence-based and referenced to current literature
Distractors are designed to test critical thinking and clinical judgment
Document is formatted for easy navigation and study
Suitable for self-assessment and group review
Content Area Overview:
Content Area Questions Key Topics Weight
Thyroid Disorders 1-100 Hypothyroidism, Hyperthyroidism, 40%
Thyroiditis, Thyroid Nodules, Thyroid
Cancer
Diabetes Mellitus 101-200 Type 1 Diabetes, Type 2 Diabetes, 40%
Gestational Diabetes, Diabetic Ketoacidosis,
Hyperosmolar Hyperglycemic State
Pharmacotherapy & Monitoring 201-230 Levothyroxine, Methimazole, Insulin 12%
Regimens, Oral Hypoglycemics, SGLT2
Inhibitors, GLP-1 Agonists
Patient Education & 231-250 Lifestyle Modifications, Hypoglycemia 8%
Complications Management, Long-term Complications,
Sick Day Rules
Page 2
,Q1. A patient with type 2 diabetes on metformin 1000 mg BID and glipizide 10 mg BID presents with acute
kidney injury (creatinine 3.0 mg/dL, eGFR 22 mL/min/1.73 m²). Which adjustment to the diabetes regimen
is most appropriate?
A. Continue metformin at reduced dose; discontinue glipizide.
B. Discontinue metformin; continue glipizide at same dose.
C. Discontinue both metformin and glipizide; start insulin glargine.
D. Continue both metformin and glipizide; add sitagliptin.
Correct Answer: C. Discontinue both metformin and glipizide; start insulin glargine.
Rationale: Metformin is contraindicated when eGFR <30 mL/min/1.73 m² due to risk of lactic acidosis. Glipizide,
a sulfonylurea, accumulates in renal impairment and can cause prolonged hypoglycemia. Both should be stopped.
Insulin glargine is safe in renal impairment because it does not require renal clearance.
Why Wrong:
A - Metformin is contraindicated at this eGFR; continuing it poses lactic acidosis risk.
B - Glipizide can accumulate and cause severe hypoglycemia in renal impairment.
D - Sitagliptin requires dose adjustment for renal impairment and does not address the need to stop metformin
and glipizide.
Reference: American Diabetes Association. (2023). Standards of Medical Care in Diabetes-2023. Diabetes Care,
46(Suppl 1), S1-S291.
Q2. A patient with type 1 diabetes on multiple daily injections reports nocturnal hypoglycemia (glucose 52
mg/dL at 3 AM) despite reducing bedtime insulin. Continuous glucose monitoring reveals a nadir at 2 AM
followed by hyperglycemia at 7 AM. Which pathophysiologic process best explains this pattern?
A. Somogyi effect
B. Dawn phenomenon
C. Waning insulin effect
D. Rebound hyperglycemia from glucagon excess
Correct Answer: A. Somogyi effect
Rationale: The Somogyi effect involves a rebound hyperglycemia following an episode of hypoglycemia, due to
counterregulatory hormone release (glucagon, epinephrine). The dawn phenomenon is a morning rise without
preceding hypoglycemia. Waning insulin effect would cause gradual hyperglycemia without a nadir.
Why Wrong:
B - Dawn phenomenon is a morning rise without preceding hypoglycemia, not a rebound.
C - Waning insulin effect would cause gradual hyperglycemia, not a nadir at 2 AM.
D - Rebound hyperglycemia from glucagon excess is part of the Somogyi effect, but the question asks for the
overall pattern name.
Reference: Cryer, P. E. (2013). Hypoglycemia in diabetes: Pathophysiology, prevalence, and prevention. American
Diabetes Association.
Page 3
, Q3. A patient with subclinical hypothyroidism (TSH 7.2 mIU/L, free T4 1.0 ng/dL) is being started on
levothyroxine. The patient also takes ferrous sulfate 325 mg daily for iron deficiency anemia. Which
instruction is most critical to ensure proper absorption?
A. Take levothyroxine with food to reduce GI upset.
B. Take levothyroxine and ferrous sulfate together to increase compliance.
C. Take levothyroxine at least 4 hours apart from ferrous sulfate.
D. Increase levothyroxine dose by 25% to compensate for interaction.
Correct Answer: C. Take levothyroxine at least 4 hours apart from ferrous sulfate.
Rationale: Iron supplements bind to levothyroxine in the GI tract, forming an insoluble complex that reduces
absorption. They should be separated by at least 4 hours. Taking with food also impairs absorption. Increasing
dose is not a standard recommendation; separation is preferred.
Why Wrong:
A - Food, especially high-fiber or iron-rich foods, also impairs levothyroxine absorption.
B - Taking together worsens the interaction, reducing bioavailability.
D - Dose adjustment is not recommended; separation is the standard approach.
Reference: Lehne, R. A. (2026). Pharmacology for Nursing Care (12th ed., Ch. 49). Elsevier.
Q4. A patient with Graves' disease is being treated with methimazole. Three weeks into therapy, the patient
develops fever, sore throat, and oral ulcers. Laboratory results show WBC 1,200/µL, absolute neutrophil
count 400/µL. What is the most appropriate immediate action?
A. Continue methimazole and add a broad-spectrum antibiotic.
B. Discontinue methimazole immediately and hospitalize for agranulocytosis management.
C. Switch to propylthiouracil and monitor CBC weekly.
D. Administer granulocyte colony-stimulating factor (G-CSF) and continue methimazole.
Correct Answer: B. Discontinue methimazole immediately and hospitalize for agranulocytosis management.
Rationale: Methimazole can cause agranulocytosis (absolute neutrophil count <500/µL), a life-threatening adverse
effect. The drug must be discontinued immediately. Hospitalization is required for infection management and
possible G-CSF therapy. Switching to propylthiouracil is not safe because of cross-reactivity.
Why Wrong:
A - Continuing methimazole in the setting of agranulocytosis is dangerous; infection management alone is
insufficient.
C - Propylthiouracil has cross-reactivity and can also cause agranulocytosis.
D - G-CSF may be used, but methimazole must be discontinued first.
Reference: Burch, H. B., & Cooper, D. S. (2015). Management of Graves disease: A review. JAMA, 314(23),
2544-2554.
Page 4
